FDA Expands Merck-Pfizer Combo Approval for Bladder Cancer Treatment

Key Facts

In a move that strengthens the position of mega-cap pharmaceutical firms in the global oncology market, the US FDA has approved the expanded use of Merck's (MRK) Keytruda in combination with Pfizer's (PFE) Padcev. This approval targets muscle-invasive bladder cancer, allowing patients to access the therapy regardless of their eligibility for cisplatin chemotherapy. This regulatory milestone is expected to significantly expand the addressable patient population for these high-revenue drugs.

This expansion comes as Keytruda continues its dominance, having generated approximately $25 billion in sales during 2023 according to Merck's annual financial reports. Meanwhile, Pfizer is aggressively scaling its oncology portfolio following its $43 billion acquisition of Seagen, the developer of Padcev, last year per market data. This combination therapy places increased competitive pressure on peers like Bristol-Myers Squibb, which maintains a presence in the same therapeutic area with its own immunotherapy offerings.

Regarding market performance, MRK shares closed at $123.54 while PFE shares stood at $24.17 (at close July 10, 2026) per market data. Investors are now looking toward broader macro catalysts, including the release of the FOMC Minutes on July 8, 2026, which may impact the interest-rate-sensitive healthcare sector. Traders are also monitoring Pfizer's support levels near its recent low of $24.10 for signs of price stabilization.